The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, US, answers the question: How do minimal residual disease negativity rates with daratumumab, carfilzomib, lenalidomide and dexamethasone combination compare to other treatment options in patients with newly diagnosed multiple myeloma?
Based on the results from a single-arm phase II study, eight cycles of weekly daratumumab, carfilzomib, lenalidomide and dexamethasone resulted in 80% MRD negativity that is a much better rate compared with carfilzomib, lenalidomide and dexamethasone alone (40-50% MRD negativity).